Prolactin is an important regulator of intestinal calcium transport

2007 ◽  
Vol 85 (6) ◽  
pp. 569-581 ◽  
Author(s):  
Narattaphol Charoenphandhu ◽  
Nateetip Krishnamra

Prolactin has been shown to stimulate intestinal calcium absorption, increase bone turnover, and reduce renal calcium excretion. The small intestine, which is the sole organ supplying new calcium to the body, intensely expresses mRNAs and proteins of prolactin receptors, especially in the duodenum and jejunum, indicating the intestine as a target tissue of prolactin. A number of investigations show that prolactin is able to stimulate the intestinal calcium transport both in vitro and in vivo, whereas bromocriptine, which inhibits pituitary prolactin secretion, antagonizes its actions. In female rats, acute and long-term exposure to high prolactin levels significantly enhances the (i) transcellular active, (ii) solvent drag-induced, and (iii) passive calcium transport occurring in the small intestine. These effects are seen not only in pregnant and lactating animals, but are also observed in non-pregnant and non-lactating animals. Interestingly, young animals are more responsive to prolactin than adults. Prolactin-enhanced calcium absorption gradually diminishes with age, thus suggesting it has an age-dependent mode of action. Although prolactin's effects on calcium absorption are not directly vitamin D-dependent; a certain level of circulating vitamin D may be required for the basal expression of genes related to calcium transport. The aforementioned body of evidence supports the hypothesis that prolactin acts as a regulator of calcium homeostasis by controlling the intestinal calcium absorption. Cellular and molecular signal transductions of prolactin in the enterocytes are largely unknown, however, and still require investigation.

1962 ◽  
Vol 203 (3) ◽  
pp. 497-505 ◽  
Author(s):  
J. D. Sallis ◽  
E. S. Holdsworth

The site of absorption of Ca45 was studied in rachitic chicks and rachitic chicks given vitamin D3. Vitamin D3 markedly increases absorption from the small intestine and, in vivo, similar amounts of calcium are absorbed along the entire small intestine. With everted gut sacs, the distal third of the small intestine transported much more calcium than did the duodenal and middle sections. Thus, interpretations of in vitro results may not always depict the natural in vivo process. Vitamin D2 had little activity in the chick, but AT-10 series 2 and AT-10 series 3 were almost as active as vitamin D3 for calcium transport. These results suggest an "active carrier" may be formed by addition of hydrogen or hydroxyl groups to the opened ring B of vitamin D, giving a carrier capable of reversible oxidation-reduction or keto-enol tautomerism. Using metabolic inhibitors, active calcium transport in vitro relied on glycolysis for its energy supply. The transport was independent of the sodium pump.


2001 ◽  
Vol 47 (1) ◽  
pp. 52-56 ◽  
Author(s):  
Kazuo HARAI ◽  
Tomio MOROHASHI ◽  
Tsuneyoshi SANO ◽  
Shoji YAMADA

1979 ◽  
Vol 64 (3) ◽  
pp. 729-736 ◽  
Author(s):  
J. C. Gallagher ◽  
B. Lawrence Riggs ◽  
John Eisman ◽  
Alan Hamstra ◽  
Sara B. Arnaud ◽  
...  

Blood ◽  
1989 ◽  
Vol 74 (1) ◽  
pp. 82-93 ◽  
Author(s):  
JY Zhou ◽  
AW Norman ◽  
M Lubbert ◽  
ED Collins ◽  
MR Uskokovic ◽  
...  

Abstract Induction of terminal differentiation of leukemic and preleukemic cells is a therapeutic approach to leukemia and preleukemia. The 1 alpha, 25- dihydroxyvitamin D3 [1,25(OH)2D3], the hormonally active form of vitamin D3, can induce differentiation and inhibit proliferation of leukemia cells, but concentrations required to achieve these effects cause life-threatening hypercalcemia. Seven new analogs of 1,25(OH)2D3 were discovered to be either equivalent or more potent than 1,25(OH)2D3 as assessed by: (a) inhibition of clonal proliferation of HL-60, EM-2, U937, and patients' myeloid leukemic cells: and (b) induction of differentiation of HL-60 promyelocytes. Furthermore, these analogs stimulated clonal growth of normal human myeloid stem cells. The most potent analog, 1,25-dihydroxy-16ene-23yne-vitamin D3, was about fourfold more potent than 1,25(OH)2D3. This analog decreased clonal growth and expression of c-myc oncogene in HL-60 cells by 50% within ten hours of exposure. Effects on calcium metabolism of these novel analogs in vivo was assessed by intestinal calcium absorption (ICA) and bone calcium mobilization (BCM). Each of the analogs mediated markedly less (10 to 200-fold) ICA and BCM as compared with 1,25(OH)2D3. To gain insight into the possible mechanism of action of these new analogs, receptor binding studies were done with 1,25(OH)2–16ene-23yne-D3 and showed that it competed only about 60% as effectively as 1,25(OH)2D3 for 1,25(OH)2D3 receptors present in HL-60 cells and 98% as effective as 1,25(OH)2D3 for receptors present in chick intestinal cells. In summary, we have discovered seven novel vitamin D analogs that are more potent than the physiologic 1,25(OH)2D3 as measured by a variety of hematopoietic assays. In contrast, these compounds appear to have the potential to be markedly less toxic (induction of hypercalcemia). These novel vitamin D compounds may be superior to 1,25(OH)2D3 in a number of clinical situations including leukemia/preleukemia; they will provide a tool to dissect the mechanism of action of vitamin D seco-steroids in promoting cellular differentiation.


1984 ◽  
Vol 247 (5) ◽  
pp. F746-F752 ◽  
Author(s):  
D. A. Bushinsky ◽  
M. J. Favus ◽  
F. L. Coe

Chlorthalidone, like other benzothiadiazides, lowers urine calcium excretion chronically. If intestinal calcium absorption did not fall or bone accretion did not increase, serum calcium and the filtered load of calcium would increase and urine calcium would return to pretreatment levels. To determine whether overall intestinal calcium absorption fell, we fed chlorthalidone (5 mg X kg body wt-1 X 24 h-1) to 10 adult male rats eating 15 g/day of a 0.6% calcium diet. Compared with 10 control rats, chlorthalidone reduced urine calcium [2.1 +/- 0.1 (SE) vs. 5.8 +/- 0.5 mg/6 days; P less than 0.001]. Fecal calcium rose (307 +/- 9 vs. 257 +/- 12; P less than 0.005) because percent intestinal calcium absorption fell (41 +/- 2 vs. 52 +/- 2; P less than 0.002). Twenty other rats given the same diet were injected subcutaneously with 1,25(OH)2D3 (50 ng/day). In these rats, chlorthalidone reduced urine calcium (23 +/- 3 vs. 59 +/- 3; P less than 0.001) and percent intestinal calcium absorption (60 +/- 1 vs. 66 +/- 1; P less than 0.01). With or without 1,25(OH)2D3, chronic administration of chlorthalidone reduces intestinal calcium absorption, and this reduction seems to be the mechanism that permits urine calcium excretion to remain low.


2011 ◽  
Vol 347 (1-2) ◽  
pp. 25-29 ◽  
Author(s):  
Sylvia Christakos ◽  
Puneet Dhawan ◽  
Angela Porta ◽  
Leila J. Mady ◽  
Tanya Seth

Sign in / Sign up

Export Citation Format

Share Document